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Abstract  
The current pandemic has highlighted the need for methodologies that can quickly and reliably 
prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 
infections. In the past decade, network medicine has developed and validated multiple predictive 
algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between 
a drug’s targets and disease genes. Here, we deployed algorithms relying on artificial 
intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs 
for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 
918 drugs that had been experimentally screened in VeroE6 cells, and the list of drugs under 
clinical trial, that capture the medical community’s assessment of drugs with potential COVID-
19 efficacy. We find that while most algorithms offer predictive power for these ground truth 
data, no single method offers consistently reliable outcomes across all datasets and metrics. 
This prompted us to develop a multimodal approach that fuses the predictions of all algorithms, 
showing that a consensus among the different predictive methods consistently exceeds the 
performance of the best individual pipelines. We find that 76 of the 77 drugs that successfully 
reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these 
drugs rely on network-based actions that cannot be identified using docking-based strategies. 
These advances offer a methodological pathway to identify repurposable drugs for future 
pathogens and neglected diseases underserved by the costs and extended timeline of de novo 
drug development. 
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Introduction 
The disruptive nature of the COVID-19 pandemic has unveiled the need for the rapid 
development, testing, and deployment of new drugs and cures. Given the compressed 
timescales, the de novo drug development process, that lasts a decade or longer, is not feasible. 
A time-efficient strategy must rely on drug repurposing (or repositioning), helping identify among 
the compounds approved for clinical use the few that may also have a therapeutic effect in 
patients with COVID-19. Yet, the lack of reliable repurposing methodologies has resulted in a 
winner-takes-all pattern, where more than one-third of registered clinical trials focus on 
hydroxychloroquine or chloroquine, siphoning away resources from testing a wider range of 
potentially effective drug candidates.  
Drug repurposing algorithms rank drugs based on one or multiple streams of information, such 
as molecular profiles1, chemical structures2, adverse profiles3, molecular docking4, electronic 
health records5, pathway analysis6, genome wide association studies (GWAS)6, and network 
perturbations6–14. As typically only a small subset of the top candidates is validated 
experimentally, the true predictive power of the existing repurposing algorithms remains 
unknown. To quantify and compare their predictive power, different algorithms must make 
predictions for the same set of candidates, and the experimental validation must focus not only 
on the top candidates, but also on a wider list of drugs chosen independently of their predicted 
rank.  
The COVID-19 pandemic presents both the societal imperative and the rationale to test drugs at 
a previously unseen scale. Hence, it offers a unique opportunity to quantify and improve the 
efficacy of the available predictive algorithms, while also identifying potential treatments for 
COVID-19. Here, we implement three recently developed network-medicine drug-repurposing 
algorithms that rely on artificial intelligence14,15, network diffusion16, and network proximity10 
(Figure 1A, B). To test the validity of the predictions, we identified 918 drugs ranked by all 
predictive pipelines, that had been experimentally screened to inhibit viral infection and 
replication in cultured cells17. We also collected clinical trial data to capture the medical 
community’s collective assessment of promising drug candidates. We find that the predictive 
power varies for the different datasets and metrics, indicating that in the absence of a priori 
ground truth, it is impossible to decide which algorithm to trust. We propose, however, a 
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multimodal ensemble forecasting approach that significantly improves the accuracy and the 
reliability of the predictions by seeking consensus among the predictive methods14,18.  
Network-based Drug Repurposing  
Repurposing strategies often prioritize drugs approved for (other) diseases whose molecular 
manifestations are similar to those caused by the pathogen or disease of interest19. To search 
for diseases whose molecular mechanisms overlap with the COVID-19 disease, we first mapped 
the experimentally identified20 332 host protein targets of the SARS-CoV-2 proteins (Table S4) 
to the human interactome21–24 (Table S3), a collection of 332,749 pairwise binding interactions 
between 18,508 human proteins (SI Section 1.1). We find that 208 of the 332 viral targets form a 
large connected component (COVID-19 disease module hereafter, Figure 2B), indicating that the 
SARS-CoV-2 targets aggregate in the same network vicinity12,25. Next, we evaluated the network-
based overlap between proteins associated with 299 diseases26 (𝑑) and the host protein targets 
of SARS-CoV-2 (𝑣 ) using the 𝑆!" 	metric26, finding 𝑆!" > 0 for all diseases, implying that the 
COVID-19 disease module does not directly overlap with the disease proteins associated with 
any single disease (Figure S1-2 and Table S7). In other words, a potential COVID-19 treatment 
cannot be derived from the arsenal of therapies approved for a specific disease, arguing for a 
network-based strategy that can identify repurposable drugs without regard for their established 
disease indication. 
We implemented three competing network repurposing methodologies (Figure 1B and SI Section 
1.4): i) The artificial intelligence-based algorithm14,15 maps drug protein targets and disease-
associated proteins to points in a low-dimensional vector space, resulting in four predictive 
pipelines A1-A4, that rely on different drug-disease embeddings. ii) The diffusion algorithm16 is 
inspired by diffusion state distance, and ranks drugs based on capturing network similarity of a 
drug’s protein targets to the SARS-CoV-2 host protein targets. Powered by distinct statistical 
measures, the algorithm offers five ranking pipelines (D1-D5). iii) The proximity algorithm10 ranks 
drugs based on the distance between the host protein targets of SARS-CoV2 and the closest 
protein targets of drugs, resulting in three predictive pipelines of which P1 relies on all drug 
targets; P2 ignores targets identified as drug carriers, transporters, and drug-metabolizing 
enzymes; and P3 relies on differentially expressed genes identified by exposing each drug to 
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cultured cells27. The low correlations across the three algorithms indicate that the methods 
extract complementary information from the network (Figure 2C, and SI Section 1.5). 
Experimental and Clinical Validation of Drug Repurposing Pipelines 
We implemented the 12 pipelines to predict the expected efficacy of 6,340 drugs in Drugbank27 
against SARS-CoV-2 and extracted and froze the predictions in the form of 12 ranked lists on 
April 15, 2020. All pipelines rely on the same input data and to maintain the prospective nature 
of the study, all subsequent analysis relies on this initial prediction list. As the different pipelines 
make successful predictions of a different subset of drugs, we identified 918 drugs for which all 
pipelines (except for P3, which predicts the smallest number of drugs) offer predictions and 
whose compounds were available in the Broad Institute drug repurposing library28 (Figure 1), and 
used two independent datasets to quantify the predictive power of each pipeline over the same 
set of drugs:  
(1) As the first ground truth we used 918 compounds  that had been experimentally screened 
for their efficacy against SARS-CoV-2 in VeroE6 cells, kidney epithelial cells derived from African 
green monkey17 (see SI Section 2). Briefly, the VeroE6 cells were pre-incubated with the drugs 
(from 8 µM down to 8 nM) and then challenged with wild type SARS-CoV-2 strain USA-WA1/2020. 
Of the 918 drugs, 806 had no detectable effect on viral infectivity (N drugs, 87.8% of the tested 
list); 35 were cytotoxic to the host cells (C drugs); 37 had a strong effect (S drugs), being active 
over a broad range of concentrations; and 40 had a weak effect (W drugs) on the virus (Figure 
3A, Table S10). As the prediction pipelines offer no guidance on the magnitude of the in vivo 
effect, we consider as positive outcomes drugs that had a strong or a weak effect on the virus 
(S&W, 77 drugs, Table 2), and as negative outcomes the drugs without detectable effect (N, 806 
drugs).  
(2) On April 15, 2020 (prediction date), we scanned clinicaltrials.gov, identifying 67 drugs in 
134 clinical trials for COVID-19 (CT415 dataset, Table S12). To compare outcomes across 
datasets, we limit our analysis to the experimentally tested 918 drugs, considering as positive 
the 37 drugs in clinical trial on the E918 list, and negative the remaining 881 drugs. As the 
outcomes of these trials are largely unknown, validation against CT415 dataset tests each 
pipeline’s ability to predict the pharmacological consensus of the medical community on drugs 
with expected potential efficacy for COVID-19 patients.  
   
5 
For the E918 experimental outcomes (Figure 4A), the best area under the curve (AUC) of 0.63 is 
provided by P1, followed by D2 (AUC = 0.58) and P3 (AUC = 0.58). For CT415 (Figure 4B), we 
observe particularly strong predictive power for the four AI-based pipelines (AUC of 0.73-0.76), 
followed by proximity P1 (AUC = 0.57) and P2 (AUC = 0.56).  
The goal of drug repurposing is to prioritize all available drugs, allowing the experimental efforts 
to limit their resources on the top-ranked ones. Thus, the most appropriate performance metric 
is the number of positive outcomes among top 𝐾 ranked drugs (precision at 𝐾), and the fraction 
of all positive outcomes among the top 𝐾 ranked drugs (recall at 𝐾). For the E918 dataset(Figure 
4C) A2 ranks 9 S&W drugs among the top 100, followed by P1 (7 drugs) and A3 and A4 (6 drugs). 
We observe similar trends for recall (Figure 4E): the A2 pipeline ranks 11.7% of all positive drugs 
in the top 100, and P1 selects 9%. Finally, A1 ranks 12 drugs currently in clinical trials among 
the top 100 in CT415, followed by A3 (11 drugs) and A2 (10 drugs), trends that are similar for 
recall (Figure 4F).  
Taken together, we find that while most algorithms show statistically significant predictive power 
(SI Section 3.1, Tables S1-2), they have different performance on the different ground truth 
datasets: the AI pipeline offers strong predictive power for the drugs selected for clinical trials, 
while proximity offers better predictive power for the E918 experimental outcomes. While 
together the twelve pipelines identify 22 positive drugs among the top 100, none of the pipelines 
offers consistent superior performance for all outcomes, prompting us to develop a multimodal 
approach that can extract the joint predictive power of all pipelines.  
Multimodal Approach for Drug Repurposing 
Predictive models for drug repurposing are driven by finite experimental resources that limit 
downstream experiments to those involving a finite number (𝐾) of drugs. How do we identify 
these	𝐾 drugs to maximize the positive outcomes of the tested list18? With no initial knowledge 
as to which of the 𝑁# = 12 predictive pipelines offer the best predictive power, we could place 
equal trust in all, by selecting the top 𝐾 𝑁#⁄  drugs from each pipeline (Union list). We compare 
this scenario with an alternative strategy that combines the predictions of the different pipelines. 
A widely used approach is to calculate the average rank of each drug over the 𝑁# pipelines29 
(Average Rank list). The alternative is to search for consensus ranking that maximizes the number 
of pairwise agreements between all pipelines15,18. As the optimal outcome, called the Kemeny 
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consensus29, is NP-hard to compute, we implemented three heuristic rank aggregation 
algorithms (RAAs) that approximate the Kemeny consensus: Borda’s count30, the Dowdall 
method31, and CRank15. For example, if the resources allow us to test 𝐾 = 120 drugs, we ask 
which ranked list offers the best precision and recall at 120: the Union list collecting the top 10 
predictions from the 12 pipelines; or the top 120 predictions of Average Rank, Borda, Dowdall, 
or CRank; or the top 120 drugs ranked by an individual pipeline.  
We find that Average Rank offers the worst performance, trailing the predictive power of most 
individual pipelines (Figure 4G-H). The Union List and Dowdall offer better outcomes, but trail 
behind the best performing individual pipelines (E918, CT415). Borda has a strong predictive 
performance for E918, but not for CT415. In contrast, CRank, that relies on Bayesian factors, 
offers a consistently high predictive performance for all datasets and most 𝐾 values. CRank 
performs equally well for two other datasets: a manually curated prospective list E74 (described 
below) and the list of clinical trials updated on 06/15/20 (C615, Figure S8). In other words, we 
find that CRank extracts the cumulative predictive power of all methods, matching or exceeding 
the predictive power of the individual pipelines across all datasets. Its persistent performance 
indicates that an unsupervised multimodal approach can significantly improve the hit rate over 
individual prediction algorithms. It also suggests that in the absence of a ground truth, the 
Kemeny consensus, which seeks a ranking with the smallest number of pairwise disagreements 
between the individual pipelines, represents an effective and theoretically principled strategy 
when each pipeline carries some predictive power. 
Network Effects 
Most computationally informed drug repurposing methods rely on chemical binding energy 
minimization and docking patterns, limited to compounds that bind either to viral proteins or to 
the host targets of the viral proteins20 (Figure 1C). A good example is remdesivir, a direct-acting 
antiviral that inhibits viral RNA polymerase32,33. In contrast, our pipelines identify drugs that target 
host proteins to induce network-based perturbations that alter the virus’s ability to enter the cell 
or to replicate within it. An example of such host-targeting drug34 is dexamethasone, which 
reduces mortality in COVID-19 patients by modulating the host immune system35. We find that 
only one of the 77 S&W drugs are known to directly target a viral protein binding target: 
amitriptyline, which targets SIGMAR1, the target of the NSP6 SARS-CoV-2 protein. In other 
words, 76 of the 77 drugs that show efficacy in our experimental screen are “network drugs”, 
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achieving their effect indirectly, by perturbing the host subcellular network. As these drugs do 
not target viral proteins or their host targets target, they cannot be identified using traditional 
binding-based methods yet are successfully prioritized by network-based methods.  
Searching for common mechanistic or structural patterns that could account for the efficacy of 
the 77 S&W drugs, we explored their target and pathway enrichment profiles (Figures S6-7), as 
well as their reported mechanisms of action, failing to identify statistically significant features 
shared by most S&W drugs. This failure is partly explained by the diversity of the S&W drugs 
(Table S10), containing antipsychotics (9S & 4W), serotonin receptor agonists (3W), non-steroidal 
anti-inflammatory drugs (2W), angiotensin receptor blockers (2W), tyrosine kinase inhibitors (5S), 
statins (1W & 2S), and others.  
As CRank extracts its predictive power from the network, we hypothesized that network-based 
patterns may help distinguish the S&W drugs from the N drugs. Indeed, we find that the targets 
of the 37 S drugs form a statistically significant large connected component (Z-Score=2.05), 
indicating that these targets agglomerate in the same network neighborhood. We observe the 
same pattern for the targets of the 40 W drugs (Z-Score=3.42). The negative network separation 
between the S and W drug targets (S$% = −0.69) indicates that, in fact, the S and the W drugs 
target the same network neighborhood. To characterize this neighborhood, we measured the 
network-based proximity of the targets of the S, W, and N drug classes to the SARS-CoV-2 
targets. We find that compared to random expectation, the N drug targets are far from the 
COVID-19 module (Figure 3C), while the S and W drug targets are closer to the COVID-19 
disease module than expected by chance. The magnitude of the effect is also revealing: the S 
drug targets are closer than the W drug targets, suggesting that network proximity is a positive 
predictor of a drug’s efficacy. 
Taken together, our analyses suggest that S&W drugs are diverse, and lack pathway-based or 
mechanistic signatures that distinguish them. We do find, however, that S&W drug target the 
same interactome neighborhood, located in the network vicinity of the COVID-19 disease 
module, potentially explaining their ability to influence viral activity, and the effectiveness of 
network-based methodologies to identify them.  
   
8 
Discussion 
A recent in vitro screen36 of 12,000 compounds in VeroE6 cells identified 100 compounds that 
inhibit viral infectivity. Yet, only 2 of the 12,000 compounds tested are FDA approved, the rest 
being in the preclinical or experimental phase, years from reaching patients. In contrast, 96% of 
the 918 drugs prioritized and screened here are FDA approved, hence should they also show 
efficacy in human cell lines, could be moved immediately to rapid clinical trials. Brute force 
screening does, however, offer an important benchmark: Its low hit rate of 0.8% highlights the 
value in prioritizing resources towards the most promising compounds. Indeed, the unsupervised 
CRank offers an order of magnitude higher (9%) hit rate among the top 100 drugs, and the top 
800 of the 6,340 drugs prioritized by CRank contains 58 of the 77 S&W drugs (Figure 4G-H). The 
hit rate can be further increased by expert knowledge. To demonstrate this point, we mimicked 
the traditional drug repurposing process whereby a physician-scientist manually inspected the 
top 10% of the CRank consensus ranking on April 15, removing drugs with known significant 
toxicities in vivo and lower-ranked members of the same drug class, and arrived at 74 drugs 
available for testing. Using the experimental design as described above, but over a wider range 
of doses (0.625 – 20µM, 0.2 MOI), we screened these 74 compounds separately from the E918 
list, and found 39 N, 10 W, and 11 S outcomes (Table S11). The resulting 28% enrichment of 
S&W drugs suggests that in the case of limited resources, outcomes are maximized by 
combining algorithmic consensus ranking with expert knowledge.  
Inspecting the CRank list and the experimental outcomes, we find two highly ranked drugs with 
strong outcomes, but not yet in clinical trials (Table 1): azelastine (CRank #10, S), an 
antihistamine used to treat upper airway symptoms of allergies, and digoxin (CRank #33, S), 
used to treat heart failure. Our findings, coupled with extensive experience in their use in the 
clinical community, argue for their consideration in clinical trials. Other highly ranked candidates 
include folic acid (CRank #16, S), or methotrexate (CRank #32, S), which impairs folate 
metabolism and attenuates host inflammatory response in autoimmune diseases. This latter 
mechanism argues that methotrexate is likely to be effective at the other end of the disease 
spectrum, i.e., in the face of profound hyperimmune response to the infection. Omeprazole 
(CRank #50, S), used to suppress gastric acid production, alters lysosome acidification and, 
along with other benzimidazoles, binds to nonstructural protein 3 (nsp3). Blocking this protein, 
which enhances the virus’s ability to evade the immune system 37, was found to interfere in viral 
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formation of SARS-CoV-238. The combination of CRank and strong outcomes highlighted a few 
other drugs that may be considered for clinical trial based on knowledge of the general 
pharmacology, including fluvastatin (CRank #199, S), an HMG-CoA reductase inhibitor used to 
lower cholesterol, but with pleiotropic effects, including anti-inflammatory effects (likely a class 
effect, as atorvastatin and pitavastatin also had similar effects); ivermectin (CRank #235, S), an 
anti-parasitic agent; and sildenafil (CRank #493, S), a phosphodiesterase-5 inhibitor.  
Taken together, the methodological advances presented here not only suggest potential drug 
candidates for COVID-19, but offer a principled algorithmic toolset to identify future treatments 
for diseases underserved by the cost and the timelines of conventional de novo drug discovery 
processes. As only 918 of the 6,340 drugs prioritized by CRank were screened, a selection driven 
by compound availability, many potentially efficacious FDA-approved drugs remain to be tested. 
Finally, it is also possible that some drugs that lacked activity in VeroE6 cells may nevertheless 
show efficacy in human cells, like loratadine (rank #95, N), which inhibited viral activity in the 
human cell line Caco-239. Ritonavir, our top-ranked drug, also showed no effect in our screen, 
despite the fact that over 42 clinical trials are exploring its potential efficacy in patients. In other 
words, some of the drugs ranked high by CRank may show efficacy, even if they are not among 
the 77 S&W drugs with positive outcomes.  
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Tables 1 
Table 1. CRank Predictions for Drug Repurposing. Top 100 consensus predictions of the drug repurposing 2 
pipelines aggregated using the CRank algorithm. The top 100 drugs contain 9 drugs with positive experimental 3 
outcomes (S&W), 3 of which are among the top 10 drugs. Drugs highlighted in purple correspond to strong outcomes 4 
(S), in orange weak outcomes (W), in green to cytotoxic drugs, while non-highlighted drugs have shown no effect (N) 5 
in VeroE6 cells.  6 
7 
No-effect
Strong
Weak
Cytotoxic
1 Ritonavir
2 Isoniazid
3 Troleandomycin
4 Cilostazol
5 Chloroquine
6 Rifabutin
7 Flutamide
8 Dexamethasone
9 Rifaximin
10 Azelastine
11 Crizotinib
12 Urea
13 Methylprednisolone
14 Dimethyl sulfoxide
15 Cortisone acetate
16 Folic acid
17 Celecoxib
18 Betamethasone
19 Prednisolone
20 Mifepristone
21 Budesonide
22 Prednisone
23 Oxiconazole
24 Megestrol acetate
25 Idelalisib
26 Econazole
27 Rabeprazole
28 Quinine
29 Ticlopidine
30 Hydrocortisone
31 Lansoprazole
32 Methotrexate
33 Digoxin
CRank Drug Name CRank 
67 Mebendazole
68 Adenosine
69 Mesalazine
70 Nevirapine
71 Belinostat
72 Mitomycin
73 Malathion
74 Ixekizumab
75 Vindesine
76 Secukinumab
77 Rifapentine
78 Bilastine
79 Clotrimazole
80 Erlotinib
81 Panobinostat
82 Warfarin
83 Busulfan
84 Goserelin
85 Hydroxyurea
86 Temsirolimus
87 Abiraterone
88 Miconazole
89 Ketorolac
90 Exemestane
91 Oxymetholone
92 Pentamidine
93 Diclofenac
94 Aminophylline
95 Loratadine
96 Fexofenadine
97 Terbinafine
98 Verapamil
99 Clopidogrel
100 Rivaroxaban
Drug NameCRank 
34 Gefitinib
35 Enzalutamide
36 Theophylline
37 Bicalutamide
38 Trabectedin
39 Nelfinavir
40 Beclomethasone dipropionate
41 Fluconazole
42 Aminoglutethimide
43 Ifosfamide
44 Hydroxychloroquine
45 Acetic acid
46 Cyclophosphamide
47 Methimazole
48 Teniposide
49 Ribavirin
50 Omeprazole
51 Chlorambucil
52 Citalopram
53 Bortezomib
54 Leflunomide
55 Dimethyl fumarate
56 Teriflunomide
57 Colchicine
58 Phenylbutyric acid
59 Progesterone
60 Triamcinolone
61 Medroxyprogesterone acetate
62 Tioguanine
63 Quercetin
64 Clobetasol
65 Letrozole
66 Etoposide
Drug Name
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Table 2 Drugs with Positive Experimental Outcomes. List of the 77 drugs with a positive outcome (S&W) from in 8 
vitro screen17. Drug response classification was obtained by a two-step model for drug response (see SI Section 2.3). 9 
Purple drugs show strong effect (S), and orange drugs showed weak effect (W).10 
11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
Strong
Weak
CRank Drug Name CRank Drug Name CRank Drug Name
Chloroquine
Rifabutin
Rifaximin
Azelastine
Folic acid
Methotrexate
Digoxin
Hydroxychloroquine
Omeprazole
Clobetasol propionate
Auranofin
Vinblastine
Fluvastatin
Clomifene
Ibuprofen
Ivermectin
Atorvastatin
Pralatrexate
Cobimetinib
Hydralazine
Propranolol
Osimertinib
Vincristine
Doxazosin
Rosiglitazone
5
6
9
10
16
32
33
44
50
113
118
120
199
210
233
235
243
253
263
269
297
317
348
367
397
Aminolevulinic acid398
Pitavastatin
Tenoxicam
Quinidine
Sertraline
Ingenol mebutate
Norelgestromin
Sildenafil
Eliglustat
Ulipristal
Cinacalcet
Perphenazine
423
431
438
456
460
463
493
499
518
553
556
558 Idarubicin
Perhexiline
Amiodarone
Duloxetine
Toremifene
Afatinib
Amitriptyline
Meclizine
Valsartan
Eletriptan
Sotalol
Thioridazine
Chlorcyclizine
Omacetaxine mepesuccinate
564
569
577
585
586
601
626
635
651
673
678
695
707
Candesartan721
Mianserin
Clofazimine
Chlorpromazine
Imipramine
Promazine
L-Alanine
Moxifloxacin
Tasimelteon
Vandetanib
Azilsartan medoxomil
Frovatriptan
Zolmitriptan
Procarbazine
Asenapine
Dyclonine
Clemastine
Prochlorperazine
Miglustat
Prenylamine
Dalfampridine
Cinchocaine
Methotrimeprazine
Methylthioninium
Metixene
742
755
767
772
830
900
917
933
995
1000
1020
1034
1035
1093
1107
1140.5
1194
1222
1224
1276
1314
1355
1396
1403
1443 Trifluoperazine
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Figures 22 
 23 
Figure 1 Network Medicine Framework for Drug Repurposing. (A) Study Design and Timeline. Following the 24 
publication of host-pathogen protein-protein interactions20 – March, 23rd, 2020 – we implemented three drug 25 
repurposing algorithms, relying on AI (A1-A4), network diffusion (D1-D5) and proximity (P1-P3), together resulting in 26 
12 predictive ranking lists (pipelines, shown in (B)). Each pipeline offers predictions for a different number of drugs, 27 
what were frozen on April 15, 2020. We then identified 918 drugs for which all pipelines but P3 offered predictions, 28 
and experimentally validated their effect on the virus in VeroE6 cells17. The experimental (E918, E74) and clinical trial 29 
lists C415 offered the ground truth for validation and rank aggregation. (C) Direct target drugs bind either to a viral 30 
protein (D1) or to a host protein target of the viral proteins (D2). Network drugs (D3), in contrast, bind to the host 31 
proteins and limit viral activity by perturbing the host subcellular network.  32 
A
Clinical Trials 
37 Drugs
881 Negative
CT415
Strong                37 
Weak                 40
Cytotoxic           35
No-Effect         806
E918 Outcomes
Strong               11 
Weak                 10
Cytotoxic           14
No-Effect           39
E74 Outcomes
Union
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Borda
Donwall
CRank
Rank Aggregation
Human Interactome
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SARS-COV2 targets
320 human proteins
Drugs
7,591drugs
4,187 drug targets
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Artificial Intelligence (A1 - A4)
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Apr 15 Jun 15 ValidationDrug Repurposing Predictions Experimental Screening
Predictions Finalized Experimental Readout
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 33 
Figure 2. COVID-19 Disease Module. (A) Proteins targeted by SARS-CoV-2 are not distributed randomly in the 34 
human interactome, but form a large connected component (LCC) consisting of 208 proteins, and multiple small 35 
subgraphs, shown in the figure. Almost all proteins in SARS-CoV-2 LCC are also expressed in the lung tissue, 36 
potentially explaining the effectiveness of the virus in causing pulmonary manifestations of the disease. (B) The 37 
random expectation of the LCC size indicates that the observed COVID-19 LCC, whose size is indicated by the red 38 
arrow, is larger than expected by chance (Z-score=1.65). (C) Heatmap of the Kendall 𝝉 statistic showing that the 39 
ranking list predicted by the different methods (A,D,P) are not correlated. We observe, however high correlations 40 
among the individual ranking list predicted by the same predictive method. 41 
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 42 
Figure 3 Experimental Outcomes and Network Origins. (A) Examples of dose-response curves for eight of the 918 43 
experimentally validated drugs17, illustrating the four observed outcomes (S, W, C and N). VeroE6 cells were 44 
challenged in vitro with SARS-CoV-2 virus and treated with the drug over a range of doses (from 8 nM to 8 µM). A 45 
two-steps drug-response model (see SI Section 2.3) was used to classify each drug into Strong, Weak, Cytotoxic or 46 
No-Effect categories, according to their response to the drug in different doses and cell and viral reduction. (B) The 47 
sub-network formed by the targets of the 77 S&W drugs within the interactome. The link corresponds to binding 48 
interactions. Purple proteins are targeted by S drugs only; orange by W drugs only; proteins targeted by both S&W 49 
drugs are shown as pie charts, proportional to the number of targets in each category. (C) The targets of N drugs 50 
have a positive proximity Z-Score to the COVID-19 module, meaning they are further from the COVID-19 module than 51 
random expectation. By contrast, the targets of S&W drugs are more proximal (closer) to the COVID-19 module than 52 
expected by change, suggesting that their COVID-19 vicinity contribute to their ability to alter the virus’s ability to 53 
infect the cells. 54 
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 55 
Figure 4 Performance of the Predictive Pipelines. (A,B) AUC (Area under the Curve), (C,D) Precision at 100, and 56 
(E,F) Recall at 100, for twelve pipelines tested for drug repurposing, each plot using as a gold standard the S&W drugs 57 
in E918 (left column) and drugs under clinical trials for treating COVID-19 as of April 15th, 2020 (CT415, right column). 58 
(G,H) The top 𝑲	precision and recall for the different rank aggregation methods (connected points), compared to the 59 
individual pipelines (empty symbols) documenting the consistent predictive performance of CRank. Similar results are 60 
shown for two other datasets in Figure S8: the prospective expert curated E74 and the clinical trial data refreshed on 61 
06/15/20 (CT615) 62 
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1 Network-Based Drug Repurposing For COVID-19 
1.1 Human Interactome and SARS-CoV-2 and Drug Targets 
The human interactome was assembled from 21 public databases that compile experimentally derived protein-
protein interaction (PPI) data: 1) binary PPIs, derived from high-throughput yeast-two hybrid (Y2H) experiments 
(HI-Union1), three-dimensional (3D) protein structures (Interactome3D2, Instruct3, Insider4), or literature curation 
(PINA5, MINT6 , LitBM171, Interactome3D, Instruct, Insider, BioGrid7, HINT8, HIPPIE9, APID10, InWeb11); 2) PPIs 
identified by affinity purification followed by mass spectrometry present in BioPlex12, QUBIC13, CoFrac14, HINT, 
HIPPIE, APID, LitBM17, and InWeb; 3) kinase substrate interactions from KinomeNetworkX15 and 
PhosphoSitePlus16; 4) signaling interactions from SignaLink17 and InnateDB18; and 5) regulatory interactions 
derived by the ENCODE consortium. We used the curated list of PSI-MI IDs provided by Alonso-Lopez et. al. 
(2019)10 for differentiating binary interactions among the several experimental methods present in the literature-
 3 
curated databases. For InWeb, interactions with curation scores < 0.175 (75th percentile) were not considered. 
All proteins were mapped to their corresponding Entrez ID (NCBI) and the proteins that could not be mapped 
were removed. The final interactome used in our study contains 18,505 proteins, and 327,924 interactions 
(Table S3). We retrieved interactions between 26 SARS-CoV-2 proteins and 332 human proteins reported by 
Gordon, et. al. (2020)19 (Table S4). We retrieved drug target information from the DrugBank database20, which 
contains 24,609 interactions between 6,228 drugs and their 3,903 targets, and drug target interaction data 
curated from the literature for 25 drugs (Table S5). We also obtained from the DrugBank database differentially 
expressed genes (DEGs) identified by exposure of drugs to different cell lines (Table S6). The Largest 
Connected Component (LCC) of human proteins that bind to SARS-CoV-2 proteins was calculated using a 
degree-preserving approach21, which prevents the repeated selection of the same high degree nodes, setting 
100 degree bins in 1,000 realizations. 
1.2 Lung Gene Expression (Fig 2A) 
We evaluated gene expression in the lung by using the GTEX database22, considering genes with a median 
count lower than 5 transcripts (raw counts) as not expressed.  
1.3 Disease Comorbidities 
Pre-existing conditions worsen prognosis and recovery of COVID-19 patients23. Previous work showed that 
the disease relevance of human proteins targeted by a virus can predict the signs, symptoms, and diseases 
caused by that pathogen24. This prompted us to identify diseases whose molecular mechanisms overlap with 
cellular processes targeted by SARS-CoV-2, allowing us to predict potential comorbidity patterns25–27. We 
retrieved 3,173 disease-associated genes for 299 diseases28, finding that 110 of the 332 proteins targeted by 
SARS-CoV-2 are implicated in other human diseases; however, the overlap between SARS-CoV-2 targets and 
the pool of the disease-associated genes was not statistically significant (Fisher’s exact test; FDR-BH padj -
value> 0.05). We evaluated the network-based overlap between the proteins associated with each of the 299 
diseases and the host protein targets of SARS-CoV-2 using the 𝑆!" metric28, where 𝑆!" < 0 signals a network-
based overlap between the SARS-CoV-2 viral targets 𝑣 and the gene pool associated with disease 𝑏. We 
 4 
found that 𝑆!" > 0	for each disease, indicating that COVID-19 disease module does not directly overlap with 
any major disease module (Figure S1 and Table S7). The diseases closest to the COVID-19 disease module 
(smallest 𝑆!") included several cardiovascular diseases and cancers, whose comorbidity in COVID-19 patients 
is well documented29–31 (Figure S2). The same metric predicted comorbidity with neurological diseases, in line 
with our observation that the host protein targets are expressed in the brain (Table S7).  
In summary, we found that the SARS-CoV-2 host protein targets do not overlap with proteins associated 
with any major diseases, indicating that a potential COVID-19 treatment cannot be derived from the arsenal of 
therapies approved for a specific disease. These findings argue for a strategy that maps drug targets without 
regard to their localization within a particular disease module. However, the disease modules closest to the 
SARS-CoV-2 viral targets are those with noted comorbidity for COVID-19 infection, such as pulmonary and 
cardiovascular diseases. We also found multiple network-based evidences linking the virus to the nervous 
system, a less explored comorbidity, consistent with the observations that many infected patients initially lose 
olfactory function and taste32, and 36% of patients with severe infection who require hospitalization have 
neurological manifestations. 
  
 5 
 
Figure S1 - Distribution of the Network Overlap Measure Svb Between 299 Diseases and COVID-19 Targets. Svb values 
represent the network-based overlap between SARS-COV2 targets v and the genes associated with each disease b. 
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Figure S2 - Disease Comorbidity Measured by the Network Overlap Between COVID-19 Targets and 299 Diseases. The 
figure represents each disease as a circle whose radius reflects the number of disease genes associated with it28. The 
diseases closest to the center, whose names are marked, are expected to have higher comorbidity with the COVID-19 
outcome. The farther a disease is from the center, the more distant are its disease proteins from the COVID-19 viral targets. 
Disease Comorbidity. We measured the network proximity between COVID-19 targets and 299 diseases. The figure 
represents each disease as a circle whose radius reflects the number of disease genes associated with it28. The diseases 
closest to the center, whose names are marked, are expected to have higher comorbidity with the COVID-19 outcome. 
The farther a disease is from the center, the more distant are its disease proteins from the COVID-19 viral targets 
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1.4 Drug Repurposing Prediction Algorithms 
1.4.1 Artificial Intelligence Based Algorithm (A1-A4) 
We designed a graph neural network for COVID-19 treatment recommendations based on a previously 
developed graph neural network (GNN) architecture33 (Figure S3).The multimodal graph is a heterogeneous 
graph 𝐺	 = 	 (𝑉, 𝑅) with 𝑁 nodes 𝑣# 	 ∈ 	𝑉 representing three distinct types of biomedical entities (i.e., drugs, 
proteins, diseases), and triplets, i.e., labeled edges (𝑣# , 𝑟, 𝑣$) 	∈ 	𝑅 representing four semantically distinct types 
of edges 𝑟 between the entities (i.e., protein-protein interactions, drug-target associations, disease-protein 
associations, and drug-disease indications). 
COVID-19 drug treatment recommendation task. We cast the COVID-19 treatment recommendation task as 
a link prediction problem on the multimodal graph. The task was to predict new edges between drug and 
disease nodes such that a predicted link between a drug node 𝑣# and a disease node 𝑣$ should indicate that 
drug 𝑣# is a promising treatment for disease 𝑣$ (e.g., COVID-19). Our graph neural network is an end-to-end 
trainable model for link prediction on the multimodal graph and has two main components: (1) An encoder: a 
graph convolutional network operating on 𝐺 and producing embeddings for nodes in 𝐺; and (2) A decoder: a 
model optimizing embeddings such that they are predictive of approved drug indications.  
Overview of graph neural architecture. The neural message passing encoder took as input a graph 𝐺 and 
produced a node d-dimensional embedding 𝑧# 	 ∈ 	𝑅% for every drug and disease node in the graph. We used 
the encoder33 that learned a message-passing algorithm34 and aggregation procedure to compute a function 
of the entire graph that transformed and propagated information across graph 𝐺34. The graph convolutional 
operator took into account the first-order neighborhood of a node and applied the same transformation across 
all locations in the graph. Successive application of these operations then effectively convolved information 
across the 𝐾&' order neighborhood (i.e., embedding of a node depends on all the nodes that are at most 𝐾 
steps away), where 𝐾 is the number of successive operations of convolutional layers in the neural network 
model. The graph convolutional operator takes the form 
 8 
𝒉#()*+) = 𝜙	(∑ ∑ 𝛼-#$ 	𝑾-())𝒉$()) + 𝛼-#𝒉#()))$∈/!" 	- ,  (1) 
where 𝒉#()) ∈ 𝑅%()) is the hidden state of node 𝑣# in the 𝑘&' layer of the neural network with 𝑑(𝑘) being the 
dimensionality of this layer’s representation, 𝑟 is an edge type, matrix	𝑾-()) is an edge-type specific parameter 
matrix, 𝜙 denotes a non-linear element-wise activation function (i.e., a rectified linear unit), and 𝛼-  denote 
attention coefficients35. To arrive at the final embedding 𝑧# 	 ∈ 	𝑅% of node 𝑣#, we compute its representation as 𝑧# =	𝒉#()). Next, the decoder takes node embeddings and combines them to reconstruct labeled edges in 𝐺. 
In particular, the decoder scores a (𝑣# , 𝑟, 𝑣$) triplet through a function 𝑔 whose goal is to assign a score 𝑔(𝑣# , 𝑟, 𝑣$)  representing how likely it is that drugs vi will treat disease vj (i.e., 𝑟  denotes an ‘indication‘ 
relationship)35.  
Training the graph neural network. During model training, we optimized model parameters using the max-
margin loss functions to encourage the model to assign higher probabilities to successful drug indications (𝑣# , 𝑟, 𝑣$)  than to random drug-disease pairs. We took an end-to-end optimization approach that jointly 
optimized over all trainable parameters and propagated loss function gradients through both the encoder and 
the decoder. To optimize the model, we trained it for a maximum of 100 epochs (training iterations) using the 
Adam optimizer36 with a learning rate of 0.001. We initialized weights using the initialization described in37. To 
make the model comparable to other drug repurposing methodologies in this study, we did not integrate 
additional side information into node feature vectors; instead, we used one-shot indicator vectors38 as node 
features. For the model to generalize well to unobserved edges, we applied a regular dropout39 to hidden layer 
units (Eq. (10)). In practice, we used efficient sparse matrix multiplications, with complexity linear in the number 
of edges in 𝐺, to implement the model. We used a 2-layer neural architecture with 𝑑+ = 	32, 𝑑0 = 	32, 𝑑# =	128 hidden units in input, output, and intermediate layer, respectively; a dropout rate of 0.1; and a max-margin 
of 0.1. We used mini-batching40 by sampling triplets R from the multimodal graph 𝐺. That is, we processed 
multiple training mini-batches (mini-batches are of size 512), each obtained by sampling only a fixed number 
of triplets, resulting in dynamic batches that changed during model training. 
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Constructing ranked lists of candidate drugs for COVID-19. We generated four lists of candidate drugs for 
COVID-19. To generate the lists, we used embeddings returned by the graph neural network, in particular, 
embeddings learned for nodes representing either COVID-19 or drugs in multimodal graph 𝐺.  The embedding 
vectors for diseases and drugs are provided in Table S8 and Table S9, respectively. The pipeline A1 searches 
for drugs that are in the vicinity of the COVID-19 disease by calculating the cosine distance between COVID-
19 and all drugs in the decoded embedding space41. The decoding is based on the 𝑁	 = 	10  nearest 
neighboring nodes in the embedding space, with a minimum distance between nodes of 𝐷	 = 	0.25. The 
pipeline A2 prevents that nodes in the decoding embedding space from packing together too closely, by using 𝐷	 = 	0.8 and keeping 𝑁 unchanged. These constraints push the structures apart into softer, more general 
features, offering a better overarching view of the embedding space at the loss of the more detailed structure. 
Pipeline A3 forces the decoding to concentrate on the very local structure by using N = 5, to explore a smaller 
neighborhood, while setting the minimum distance at a midrange point of D = 0.5. Pipeline A4 focuses on a 
broader view of the embedding space by setting N=10 and D = 1. Finally, to obtain lists of candidate drugs, 
each pipeline ranked drugs based on the pipeline-defined distances of drugs to COVID-19 (Figure S3). 
Intuitively, parameter 𝑁  constrained the size of the local neighborhood each pipeline looked at in the 
embedding space when calculating the distances, and parameter 𝐷 controlled how tightly the pipeline was 
allowed to pack the embeddings together. 
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Figure S3 - Overview of AI-based Strategy for Drug Repurposing. (A) Visualization of the learned embedding space. Every 
point represents a drug (in blue) or a disease (in orange). If a drug and a disease are embedded close together in this 
space, this means the local interaction neighborhoods of the drug and the disease in the multimodal graph are predictive 
of whether the drug can treat the disease. (B) Testing of the graph neural network (GNN) model. Probability distributions 
of approved indications and non-indications (i.e., random drug-disease pairs) learned by the GNN model are well-
separated, indicating the model can distinguish between true indications and random drug-disease pairs. (C) Predictive 
performance of the GNN model on the test set of drug indications that were held-out during model training. Higher values 
indicated better performance (AUROC, Area under the ROC curve; AUPRC, Area under the PR curve; MAP@50, Mean 
average precision at top 50). 
 
1.4.2 Diffusion-Based Algorithms (D1-D5) 
The diffusion state distance (DSD)42 algorithm uses a graph diffusion property to derive a similarity metric for 
pairs of nodes that takes into account how similarly they affect the rest of the network. We calculate the 
expected number of times 𝐻𝑒(𝐴, 𝐵) that a random walker starting at node 𝐴 visits node 𝐵, representing each 
node by the vector42: 
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𝐻𝑒	(𝑉#) = [𝐻𝑒(𝑉# , 𝑉+), 𝐻𝑒(𝑉# , 𝑉0), 𝐻𝑒(𝑉# , 𝑉1), … ,𝐻𝑒(𝑉# , 𝑉2)],   (2) 
which describes how a perturbation initiated from that node affects other nodes in the interactome. The 
similarity between nodes 𝐴 and 𝐵 is provided by the L1-norm of their corresponding vector representations: 
𝐷𝑆𝐷(𝐴, 𝐵) = ||𝐻𝑒(𝐴) − 𝐻𝑒(𝐵)||.  (3) 
Inspired by the DSD, we developed five new metrics to calculate the impact of drug targets 𝑇 on the SARS-
CoV-2 targets 𝑉. The first (Pipeline D1) is defined as: 
𝐼3435#2 = +||7|| 	∑ min!∈8 𝐷𝑆𝐷	(𝑡, 𝑣)&∈7 ,   (4) 
where 𝐷𝑆𝐷(𝑠, 𝑡) represents the diffusion state distance between nodes 𝑡 and 𝑣. Since the L1-norm of two 
large vectors may result in loss of information43, we also used the metrics (Pipeline D2): 
𝐼9:5#2 = +||7|| 	∑ min!∈8 𝐾𝐿	(𝑡, 𝑣)&∈7    (5) 
 and (Pipeline D3): 
𝐼9:5;% = +||7|| 	∑ median!∈8 𝐾𝐿	(𝑡, 𝑣)&∈7 ,  (6) 
where 𝐾𝐿 is the Kullback-Leibler (𝐾𝐿) divergence between the vector representations of the nodes	𝑡 and 𝑠. 
Finally, to provide symmetric measures, we tested the metrics (Pipeline D4): 
𝐼<45#2 = +||7|| 	∑ min!∈8 𝐽𝑆	(𝑡, 𝑣)&∈7    (7) 
and (Pipeline D5) 
𝐼<45;% = +||7|| 	∑ median!∈8 𝐽𝑆	(𝑡, 𝑣)&∈7 .   (8) 
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where 𝐽𝑆 is the Jensen Shannon (𝐽𝑆) divergence between the vector representations of nodes 𝑡 and 𝑠. All five 
measures assume 𝑡	 ≠ 𝑠. 
1.4.3 Proximity Algorithm (P1-P3) 
Given 𝑉, the set of COVID-19 virus targets, 𝑇, the set of drug targets, and 𝑑(𝑣, 𝑡), the shortest path length 
between nodes 𝑣	 ∈ 	𝑉 and 𝑡	 ∈ 	𝑇 in the network, we define21: 
𝑑=(𝑉, 𝑇) = +||7||∑ min!∈8 𝑑(𝑣, 𝑡)&∈7 .  (9) 
We determined the expected distances between two randomly selected groups of proteins, matching the size 
and degrees of the original V and T sets. To avoid repeatedly selecting the same high degree nodes, we use 
degree-binning21. The mean 𝜇%(8,7) and standard deviation 𝜎%(8,7) of the reference distribution allows us to 
convert the absolute distance 𝑑=to a relative distance 𝑍%=, defined as:  
𝑍%# =	 %#?	A$#(8,7)B$#(8,7) .   (10) 
We implemented three versions of the proximity algorithm: 1) relying on all drug targets (P1); 2) ignoring drug 
targets identified as drug carriers, transporters, and drug-metabolizing enzymes (P2); and 3) on differentially 
expressed genes (DEGs) identified by exposure of each drug to cultured cells, which was obtained from 
DrugBank’s compilation of 17,222 DEGs linked to 793 drugs in multiple cell lines (Table S6). 
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1.5 Network Properties of Prediction Algorithms 
1.5.1 Explanatory Subgraphs 
For each pipeline, we identified “explanatory subgraphs” to help understand the predictions made by the 
respective pipeline. The key idea was to summarize where in the data the pipeline looks for evidence for their 
predictions. Given a particular prediction, an explanatory subgraph is a small sub-network of the entire network 
considered by the pipeline that is most influential for the prediction and contributes most to the predictive 
power. For the proximity method (P), the explanatory subgraphs can be derived exactly, representing the set 
of nodes contributing to proximity. For the artificial intelligence-based methods (A), the subgraphs were 
extracted using a GNN Explainer algorithm44. GNNExplainer specifies an explanation as a subgraph of the 
entire network the GNN was trained on, such that the subgraph maximizes the mutual information with the 
GNN’s prediction. This is achieved by formulating a mean field variational approximation and learning a real-
valued graph mask, which selects the important subgraph using counterfactual reasoning. For the diffusion 
method, we first identified the SARS-CoV-2 targets (seeds) that have the maximum (or median, depending on 
the pipeline) similarity with the drug targets under consideration. Once the seeds are identified for each drug 
target, we extract the vector representation of the target and the corresponding seeds. Each element of these 
vectors corresponds to a node in the network: 
𝑡: [𝑟+, 𝑟0, 𝑟1, … , 𝑟2] 
𝑠: [𝑤+, 𝑤0, 𝑤1, … , 𝑤2] 
Each pipeline performs an element-wise comparison of these two vectors to calculate similarity values, defined 
as similarity terms, using: 
𝑡𝑒𝑟𝑚#343(𝑡, 𝑠) = |𝑟# −𝑤#|  (11) 
𝑡𝑒𝑟𝑚#9:(𝑡, 𝑠) = 𝑟# log d-"C"e (12) 
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𝑡𝑒𝑟𝑚#<4	(𝑡, 𝑠) = +0 [𝑟# log d -"5"e + 𝑤# log(C"5")], 𝑚# =	 -"*	C"0 	  (13) 
These distance similarity terms collectively contribute to each drug’s ranking score. Among all 18,446 nodes, 
we are only interested in those whose variations lead to the current ranking (drug prediction scores). Therefore, 
we applied a feature selection algorithm to eliminate the network nodes (features) that do not contribute to the 
predicted scores (outcomes). This task is done by training a regression tree model (DecisionTreeRegressor 
model, from Python 3 scikit-learn package) where feature values are the similarity terms (as defined above) 
between drug targets and the corresponding seeds. This resulted in 2,507 important features for pipeline D1 
(DSD-min), 2198 for D2 (KL-min), 2,263 for D3 (KL-med), 1,655 for D4 (JS-min), and 1,817 for D5 (JS-med). 
Important features are those with non-zero importance value as characterized by the Regressor model. 
Once the important features/nodes are extracted, we search this space to identify the explanatory 
network of each set of drug targets. To do so, we rank the similarity terms of each target and the corresponding 
seeds on the space of important features and identify the nodes with the highest contribution to the similarity 
measure such that they satisfy the following equation: 
log+D d E&;-5"e 	≤ 1, 𝑙 = max(𝑡𝑒𝑟𝑚#) , 𝑖 ∈ 𝑉  (14) 
If a drug has multiple targets or if each target has multiple corresponding seeds (seeds with the same 
similarity to a target), the results are aggregated. The explanatory network of a target that happens to be a 
seed is that seed itself. 
Figure S4 shows the similarities and differences among the explanatory subgraphs of the different 
prediction pipelines. 
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Figure S4 - Similarities and Differences of the Explanatory Subgraphs. (A) Distribution of the size of the subnetworks 
predicted varies according to the method. The AI methods have a smaller variance in the size, while methods based on 
proximity tend to have higher variances. (B) Gene overlap of the methods involved with subgraphs for each method. 
Proximity and Diffusion bases methods explore the PPI in a much vast and diverse way than the AI methods (C) Methods 
inside the same pipeline tend to select similar genes, the similarity of selected genes across methods is different (Jaccard 
Index), those genes, interestingly, also do not lie in similar neighborhood (similarity), meaning that not only do the genes 
not overlap across methods, but the vicinity the methods explore are also different. (D) Another measure used to 
understand methods similarity involved using the PCA of gene drug pairs, showing that AI methods are fairly consistent in 
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what they observe, and similarly, P1 and P2. Diffusion methods have a higher variance in gene-drug pair predictions and 
have a larger spread of their module; as expected, P3 is far from other proximity measures. 
 
1.5.2 Complementarity of Prediction Algorithms (Fig 2C) 
To investigate the complementarity among the prediction algorithms, for each drug we measured the network 
separation 𝑆F?%  between the explanatory subgraph 𝐺 and the drug’s targets (𝑑), and the separation 𝑆F?! 
between 𝐺 and the 332 SARS-Cov2 viral targets (𝑣) capturing the disease module. Each drug has twelve 
subgraphs, each corresponding to one of the twelve pipelines. A total of 320 drugs, for which all pipelines 
have predictive subgraph and separation values, are shown in Figure S5. Proximity Pipeline 3 uses differentially 
expressed genes as input drug data; thus, for proximity P3 we computed the separation between the subgraph 
and the differentially expressed genes. The figure shows complementarily patterns between methods: the AI 
pipelines extracts their predictions from subgraphs that overlap with the drug targets (𝑆F?% < 0), but are 
separated from the COVID-19 module (𝑆F?! > 0); proximity-based methods show the opposite pattern – for 
most of the predictive subgraphs the overlap with the COVID-19 module is apparent (𝑆F?! < 0); by contrast,  
diffusion-based predictive subgraphs avoid both the drug targets and the disease module (𝑆F?% > 0, 𝑆F?! >0).  
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Figure S5 - The Separation Plot for 320 Drugs. For each drug, we identified the predictive subgraph for each predictive 
pipeline. For each subgraph G, we compute the separation between the subgraph G and drug targets as SG-D and 
separation between the subgraph and SARS-CoV-2 targets as SG-V. We plot each subgraph as a dot with the two 
separation values as coordinates to form the plot above. (A) a schematic showing the network pattern represented by each 
quadrant; (B)-(D): plot for subgraphs in AI, Diffusion, Proximity pipelines, respectively. Each method’s subgraphs locate in 
different regions in the plot, suggesting that they use complimentary regions of the PPI to make predictions.  
 18 
2 Experimental Validation 
2.1 Cell Cultivation and Viruses Used 
VeroE6 cells were obtained from ATCC (Manassas, VA, USA) and maintained in DMEM supplemented with 
10% Fetal bovine serum (FBS) at 37°C in a humidified CO2 incubator. The virus strain used was isolated from 
a traveler returning to Washington State, USA, from Wuhan, China, (USA-WA1/2020) and was obtained from 
BEI resources (Manassas, VA, USA). The virus stock was passaged twice on Vero cells by challenging the cells 
at an MOI of less than 0.01 and incubating until cytopathology was seen (typically 3 d after inoculation). A 
sample of the culture supernatant was sequenced by next gen sequencing (NGS) and was consistent with the 
original isolate without evidence of other virus or bacterial contaminants. The virus stock was stored at -80°C.  
 
2.2 Virus Infection Inhibition Assay 
For evaluation of small molecule efficacy against infection with wild type SARS-CoV-2 virus, compounds were 
first dissolved to 10 mM in DMSO and then diluted into culture medium before addition to cells. The compound 
stock was added to Vero cells incubated for a minimum of 1 h and then challenged with virus at a MOI of less 
than 0.2. Dosing ranged from a final concentration of 25 µM down to 0.2 µM in a two-fold dilution series.  As 
a positive control, 5 µM E-64 was used as it was previously reported to inhibit SARS-CoV-2 infection (Hoffman 
et al. 2020). Negative controls were <0.5% DMSO. After 1-2 day incubation, cells were treated with 10% 
buffered formalin for at least 6 h, washed in PBS, and virus antigen stained with SARS-CoV-2 specific antibody 
(Sino Biologicals, MM05) together with Hoechst 33342 dye to stain cell nuclei. Plates were imaged by a Biotek 
Cytation 1 microscope, and automated image analysis was used to count total number of infected cells and 
total cell nuclei. CellProfiler software (Broad Institute, MA, USA) was used for image analysis using a customized 
processing pipeline (available upon request to RAD). Infection efficiency was calculated as the ratio of infected 
cells to total cell nuclei. Loss of cell nuclei was used to flag treatments suggestive of host cell toxicity. Where 
possible, EC50 values were calculated using dose-response models fitted by Graphpad Prism software. If a 
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compound was active at the highest dose but an EC50 value could not be calculated due to insufficient activity, 
the percent inhibition of infection at 25 µM was used to rank potency. Each assay was performed in duplicate 
in 384 well plates.  
 
2.3 Drug-Response Classification 
The classification of the drug-response outcomes was done using a drug response curve (DRC) model45. We 
used the R package drc46 to calculate the DRCs using a log-logistic model with four parameters (hill, IC50, 
min, and max). Each drug-response was classified in two steps: first inspecting toxicity and later evaluating 
the drug effect on the inhibition of viral proliferation. 
To inspect the cytotoxicity, we first estimated the model parameters using as response variable the nuclei 
count in the treated cells, normalized by the nuclei count in the controls. We tested the dose-response effect 
for all drugs using a 𝜒0 test for goodness of fit and drugs with p < 0.01 (Bonferroni correction) were defined as 
cytotoxicity, with the exception of drugs with toxicity only at the last dose concentration. To evaluate inhibition 
of viral replication, we used as response for the DRC model the number of infected cells in the treated samples 
normalized by the controls. For that, a drug was considered to have a dose-response effect by using a 𝜒0 test 
for goodness of fit (p < 0.01, Bonferroni correction), and the significant drugs were defined as Strong (S) or 
Weak (W) if the viral reduction was greater than 80% and 50%, respectively. The drugs that did not meet the 
criteria for S or W were classified as no-effect (N). Finally, we classified drugs as cytotoxic (C) if their toxicity 
curves were greater than their viral proliferation curves in at least half of the doses tested.  
2.4 Biological Interpretation of Effective Drugs in E918 Dataset  
We observed 77 drugs that showed strong (S) or weak effects (W) in the high-throughput screening. There 
was no drug category (ATC Classification) that was enriched among the S, W, or S&W drugs (hypergeometric 
test FDR-BH padj > 0.05). To search for common patterns that could explain their bioactivity, we performed 
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hierarchical clustering on the drug target profiles, failing to find binding patterns shared by all drugs (Figure S6). 
Only four small groups of drugs are observed, documenting various degrees of shared targets (Figure S6), 
three of which contain drugs from multiple categories, and one group consists of 7 nervous system-related 
drugs with similar target profiles. We also performed pathway enrichment analysis to identify biological 
processes shared across the targets of drugs with strong or weak effects. Among the 77 S&W drugs, 42 are 
located in three groups associated with common pathways, and 20 of these drugs are of diverse indications 
linked to transport and metabolism of different substrates. Eighteen are associated with pathways related to 
membrane receptors, most of them indicated for nervous system disorders, targeting G protein-coupled 
receptors such as ADRA1A, HTR2A, and HRH1 (Figure S7). Taken together, neither the pathway nor the target 
analysis reveals patterns that could explain the efficacy of the 77 S&W drugs. 
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Figure S6 – Hierarchical Clustering Highlights Groups of Drugs with Similar Target Profiles. Heatmap showing 77 S&W 
drugs from the E918 dataset and their respective targets (colored cells). Clustering performed using Euclidean distance 
and single linkage. 
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Figure S7 – Pathway Enrichment. Heatmap showing successful (S&W) drugs in the E918 dataset and their respective 
Reactome pathways in which their targets are enriched. Hierarchical clustering (Euclidean, single linkage) highlights different 
groups of drugs with similar pathway profiles. We highlight the pathways for three drug clusters, emphasizing the proteins 
targeted in one exemplary pathway for each cluster 
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3 Statistical Validation 
3.1 Performance Evaluation using ROC Curves, Precision, and Recall 
We examined whether positive drugs (e.g., strong-effect drugs) were ranked high by measuring the predictive 
power of each pipeline in terms of area under the ROC (Receiver Operating Characteristics) curve, precision, 
and recall. First, we calculated ROC (Receiver Operating Characteristics) curves and AUC (area under the 
curve) scores for model selection and performance analysis. The AUC score measures the separation between 
positive examples (e.g., drugs with strong or weak responses) and negative examples (e.g., drugs showing 
no-effect in experimental screening). For the ranked lists of drugs, we applied different thresholds to compute 
false-positive and true-positive rates to plot the ROC curves. Scores of AUC range between 0 and 1, where 1 
corresponds to perfect performance and 0.5 indicates the performance of a random classifier. We used the 
Python package Scikit-learn47 for computing the AUC scores and plotting the ROC curves.  
The AUC metric operates on the whole ranked list of drugs, and thus it does not directly reflect the ability of 
the method to prioritize most promising drug candidates at the top of the list. To address this issue and account 
for unbalanced ground-truth information where negative examples vastly outnumber positives, we also 
considered hit-rate based metrics to evaluate the quality of top-K drugs in each ranked list. Here, we evaluated 
performance at a given cut-off rank K, considering only the topmost predictions by the pipeline. In particular, 
we calculated the fraction of top-K ranked drugs that were positive outcomes (precision at K) and the fraction 
of all positive outcomes that were among the top-K ranked drugs (recall at K). 
We considered three types of ground-truth information to evaluate prediction performance:  
1) The outcome of the experimental screening of 918 compounds (E918 dataset, Table S10). We 
identified 806 no effect drugs, 40 with weak effect, and 37 with strong effect. 
2) The outcome of the experimental screening of additional 74 compounds tested with a wider range of 
doses (0.625 – 20μM, 0.2 MOI) (E74 dataset, Table S11) (Figure S8). The E74 dataset represents a 
subset of 81 compounds by a medical doctor among the top 10% of all drug predictions that were 
available for purchase. We identified 39 no effect drugs, 10 with weak effect, and 11 with strong effect. 
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3) 67 drugs that, as of April 2020, were in ongoing trials for COVID-19, obtained from the 
ClinicalTrials.gov website** (CT415 dataset, Table S12). ClinicalTrials.gov organizes COVID-19 specific 
collection of all trials. Trial records consist of information on inclusion and exclusion criteria, details on 
drugs being tested, the scientific team behind the study, and funding agencies. We extract drug 
names from clinical trials’ treatment information and match their names with records on the DrugBank 
database20. 
4) We also collected clinical trials data at the experimental readout time 6/15/2020 (C615 dataset) (Table 
S13). 
Note that some methods do not provide prediction for every drug in the full dataset. While that would make a 
fair comparison of the methods challenging, we note that ground-truth information described above is available 
for drugs predicted by all pipelines (except for P3, hence it is harder to compare this pipeline with the other 
11). Finally, we note that we adopted a conservative approach by evaluating predictive performance using the 
rankings across all 6,340 drugs, not only 918 experimentally screened drugs. For example, it is possible to 
conceive that a particular topmost prediction in a pipeline represents a positive drug, however, that is 
impossible to know if the predicted drug was not included in experimental screening. Because of that, the 
reported precision and recall values represent conservative estimates of prediction performance, i.e., the 
values are lower than what one could obtain if the analysis was limited to only experimentally screened drugs. 
To determine the significance of predictive power, we calculated the expected number of positive drugs among 
top-K drugs for each pipeline and compared the expected values with the observed precision and recall values. 
To this end, we calculated the expected number of positive drugs by taking into account (a) the number of 
drugs for which ground-truth information is available, and (b) the number of drugs for which a pipeline makes 
predictions. We used an exact one-tailed binomial test (p-value < 0.05) to test whether a top-K list returned by 
a pipeline is biased towards containing more positive drugs than what we would expect on average by pure 
chance had the ranking be a random one. 
 
** Clinical Trial Covid-19 selection: https://clinicaltrials.gov/ct2/results?cond=COVID-19 
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Figure S8 - Performance of the Different Predictive Pipelines. (A,B) AUC (Area under the Curve), (C,D) precision at 100, 
and (E,F) recall, for twelve pipelines tested for drug repurposing, using as a gold standard the S&W drugs in E74 (left panel, 
experimentally validated dataset from expert curation and drug selection) and CT615 (right panel, drugs in clinical trials 
until July 15th 2020). (G,H) The top precision and recall for the different rank aggregation methods (connected points), 
compared to the individual pipelines (empty symbols) documenting the strong predictive performance of CRank. CT06 
presents, in most cases, higher hit rates, precision and recalls when compared to E74. 
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Table S1 – Performance evaluation using the E918 dataset as ground-truth (Fig 4C,E) 
 Precision@100 Recall@100 
CRank 9% (0.750%, p=7.01 x 10-8) 11.7% (0.9%, p=2.61 x 10-8) 
P1 7% (0.467%, p=3.77 x 10-7) 9.1% (0.6%, p=2.52 x 10-7) 
P2 0% (0.458%, p=1.00) 0% (0.5%, p=1.00) 
P3 5% (2.453%, p=0.090) 6.5% (2.3%, p= 0.031) 
D1 2% (0.062%, p=0.001) 2.6% (0.1%, p=9.32 x 10-4) 
D2 2% (0.075%, p=0.002) 2.6% (0.1%, p=2.29 x 10-3) 
D3 1% (0.062%, p=0.061) 1.3% (0.1%, p=0.061) 
D4 1% (0.037%, p=0.037) 1.3% (0.1%, p=0.037) 
D5 1% (0.062%, p=0.061) 1.3% (0.1%, p=0.061) 
AI1 4% (2.779%, p=0.302) 5.2% (3.3%, p=0.024) 
AI2 9% (2.922%, p=0.002) 11.7% (3.7%, p=2.14 x 10-3) 
AI3 6% (2.635%, p=0.047) 7.8% (3.2%, p=0.037) 
AI4 6% (2.922%, p=0.049) 7.8% (3.5%, p=0.054) 
The values in the brackets represent expected values, i.e. expected Recall@100 or expected Precision@100, followed by 
p-values 
 
Table S2 – Performance evaluation using the CT415 dataset (Fig 4D,F) 
 Precision@100 Recall@100 
CRank 12% (0.360%, p=3.06 x 10-15) 32.4% (0.5%, p=2.17 x 10-19) 
P1 1% (0.224%, p=0.201) 2.7% (0.6%, p=0.202) 
P2 0% (0.220%, p=1.00) 0.0% (0.6%, p=1.00) 
P3 2% (1.790%, p=0.538) 5.4% (2.6%, p=0.245) 
D1 0% (0.030%, p=1.0) 0% (0.1%, p=1.00) 
D2 0% (0.036%, p=1.0) 0% (0.1%, p=1.00) 
D3 0% (0.030%, p=1.0) 0% (0.1%, p=1.00) 
D4 0% (0.018%, p=1.0) 0% (0.1%, p=1.00) 
D5 0% (0.302%, p=1.0) 0% (0.1%, p=1.00) 
AI1 12% (1.335%, p=7.39 x 10-9) 32.4% (2.3%, p=2.41 x 10-11) 
AI2 10% (1.404%, p=1.29 x 10-6) 27.0% (2.3%, p=8.25 x 10-9) 
AI3 11% (1.267%, p=4.52x x 10-8) 29.7% (2.3%, p=4.74 x 10-10) 
AI4 9% (1.404%, p=1.06 x 10-5) 24.3% (2.3%, p=1.26 x 10-7) 
The values in the brackets represent expected values, i.e. expected Recall@100 or expected Precision@100, followed by 
p-values 
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4 Rank Aggregation Algorithms (RAAs) 
Rank aggregation is concerned with how to combine several independently constructed rankings into one final 
ranking that represents a consensus ranking, i.e., a collective opinion of prediction methods that is 
representative of all rankings returned by the methods48. The classical consideration for specifying the final 
ranking is to maximize the number of pairwise agreements between the final ranking and each input ranking. 
Unfortunately, this objective, known as the Kemeny consensus, is NP-hard to compute48,49, which has 
motivated the development of methods that either use heuristics or approximate the Kemeny optimal 
ranking48,50–52.  
4.1 Average Rank Method 
The Average Rank method follows the most straightforward way to integrate multiple rankings. For each drug, 
it calculates a simple rank average over 12 rankings returned by the pipelines to obtain the overall ranking. 
While the Average Rank method is a popular ad-hoc rank aggregation strategy, many studies53–55, including 
ours, found that studying the average ranks can be a poor aggregation approach. Next, we briefly overview 
methods that realize more sophisticated approaches to obtain the overall ranking.  
4.2 Borda Method 
The Borda method56 is one of most commonly used rank aggregation methods. Briefly, the method proceeds 
as follows. Given are 𝑘 rankings exist, 𝑅+, 𝑅0, … , 𝑅). For each drug 𝑎 ∈ 𝑅#, 𝑎 is assigned a score 𝐵#(𝑎) equal to 
the number of drugs that 𝑎 outranks in ranking 𝑅# . The Borda count 𝐵(𝑎) of drug 𝑎 is then calculated as ∑ 𝐵#(𝑎))#G+ . Finally, drugs are sorted in the descending order based on their Borda counts to create a 
consensus ranking. Theoretically, Borda method offers a guarantee on approximating Kemeny consensus. In 
particular, Borda method is a 5-approximation algorithm of the Kemeny optimal ranking51.  
4.3 Dowdall Method 
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The Dowdall method57 is a modified form of the Borda method that has been widely used in political elections 
in many countries. Intuitively, individual pipelines make predictions for drugs, which are interpreted as 
preferences of the pipeline. For a pipeline, its 1st choice gets a score of 1, its 2nd choice get 1/2, its 3rd choice 
gets 1/3, and so on. Drug with the largest total score across pipelines wins. Formally, let be given 𝑘 rankings, 𝑅+, 𝑅0, … , 𝑅). For each drug 𝑎 ∈ 𝑅#, 𝑎 is first assigned a score 𝐷#(𝑎) equal to the reciprocal of drug’s rank in 
ranking 𝑅# . The total score 𝐷(𝑎) is then calculated as ∑ 𝐷#(𝑎))#G+ . Candidates are sorted in descending order 
based on their total score to create a consensus ranking. 
4.4 CRank 
The CRank algorithm58 starts with ranked lists of drugs, 𝑅-, each one arising from a different pipeline, r. Each 
ranked list is partitioned into equally sized groups, called bags. Each bag 𝑖 in ranked list 𝑅-  has attached 
importance weight 𝐾-#   whose initial values are all equal. CRank uses a two-stage iterative procedure to 
aggregate the individual rankings by taking into account uncertainty that is present across ranked lists. After 
initializing the aggregate ranking 𝑅 as a weighted average of ranked lists 𝑅-, CRank alternates between the 
following two stages until no changes were observed in the aggregated ranking 𝑅. (1) First, it uses the current 
aggregated ranking 𝑅 to update the importance weights 𝐾-# for each ranked list. For that purpose, the top-
ranked drugs in 𝑅  serve as a temporary gold standard. Given bag 𝑖  and ranked list 𝑅- , CRank updates 
importance weight 𝐾-# based on how many drugs from the temporary gold standard appear in bag 𝑖 using 
Bayes factors59,60. (2) Second, the ranked lists are re-aggregated based on the importance weights calculated 
in the previous stage. The updated importance weights are used to revise 𝑅 in which the new rank 𝑅(𝑎) of 
drug 𝑎 is expressed as: 𝑅(𝑎) = 	∑ 𝐾-#!(H)	𝑅-(𝑎)- , where 𝐾-#!(H) indicates the importance weight of bag 𝑖-(𝑎) of 
drug 𝑎 for ranking 𝑟, and 𝑅-(𝑎) is the rank of 𝑎 according to 𝑟. By using an iterative approach, CRank allows 
for the importance of a ranked list returned by an individual pipeline not to be predetermined, i.e., a-priori fixed, 
and to vary across drugs. The final output is a global ranked list 𝑅 of drugs that represents the collective opinion 
of all drug repurposing prediction algorithms. In all experiments, we set the number of bags to 1,000, the size 
of the temporary gold standard to 0.5% of the total number of drugs in 𝑅, and the maximum number of 
iterations to 50. In all cases, the algorithm converged, in fewer than 20 iterations59,60. The pipelines’ ranked lists 
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and CRank’s aggregation are provided in Table S14. The Python source code implementation of CRank is 
available at https://github.com/mims-harvard/crank (raa.py). 
4.5 Comparison of RAAs 
What explains CRank’s outstanding performance across all datasets? Each RAA aims to approximate the 
optimal Kemeny consensus, which offers the best agreement with all 12 prediction pipelines. As this consensus 
remains unknown (NP-hard), we cannot assess how well the different RAA methods approximate it. We do, 
however, have a ground-truth ranking, offered by the experimental and clinical datasets (E918 and CT415). 
We assigned rank 1 to the strong drugs, rank 2 to the weak drugs, and rank 3 to the no-effect drugs, allowing 
us to measure the Kemeny score for each aggregated list, representing the fraction of pairwise disagreements 
between the respective ranked list and the experimental outcomes. For	K = 100, the Kemeny score of the 
Average Rank method is infinite for E918, as there are no positive drugs among the top 100. In contrast, for 
the Borda count, we obtain a Kemeny score of KS = 0.7131, indicating that 71% of all drug pairs in the ranked 
list of Borda method disagrees with the ground-truth ranking in the E918 dataset. Note that the theoretical 
expectation for a purely random ranking is KS = 0.5, meaning that 50% of all drug pairs in the random reference 
are flipped, i.e., while with KS = 0.4545 Dowdall does better than random, we observe a much lower KS = 
0.2679 for CRank. We measured the Kemeny score for multiple values, for both datasets (E918 and CT415), 
finding that for K<250 (top drugs), CRank offers the best agreement with the outcomes. 
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5 Supplementary Tables 
Table S3 – Protein-Protein Human Interactome. 332,749 pairwise binding interactions between 18,508 human 
proteins. 
 
Table S4 - SARS-COV2-Human Interactome. Protein-protein interactions between 29 SARS-COV2 proteins 
and 332 human proteins detected by affinity purification followed by mass spectrometry (dataset retrieved from 
Gordon et al (2020)). 
 
Table S5 – List of drugs and their respective targets retrieved from the DrugBank database. 
 
Table S6 – List of 17,222 differentially expressed genes identified by exposure of 793 drugs in different cell 
lines. Data obtained from the DrugBank database. 
 
Table S7 - Network Overlap Between 299 Diseases and SARS-COV2 Targets. The Svb measure captures the 
network-based overlap between SARS-COV2 targets v and the gene pool associated with disease b. 
 
Table S8 - Embedding vectors. Representations of diseases as learned by the GNN model. Each row in the 
file contains the embedding vector for a particular disease. 
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Table S9 - Embedding vectors. Representations of drugs as learned by the GNN model. Each row in the file 
contains the embedding vector for a particular drug. 
 
Table S10 – The E918 dataset. List of 918 drugs screened for their efficacy in inhibiting SARS-CoV-2 in VeroE6 
cells and their experimental outcome. 
 
Table S11 - The E74 dataset. Experimental outcomes of 74 compounds selected by a medical doctor among 
the top 10% of all drug predictions that were available for purchase. 
 
Table S12 - Drugs Under Evaluation in Clinical Trials for Treating COVID-19 (as of April 2020) (C415 dataset). 
 
Table S13 - Drugs Under Evaluation in Clinical Trials for Treating COVID-19 (as of June 2020) (C615 dataset). 
 
Table S14 – Drug Rankings. Ranking of each drug obtained by the 12 pipelines and their aggregation with 
CRank. 
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